Latest stories on IVVD
Invivyd presents measles antibody candidate VMS063 data at IDWeek 2026
The Fly58 · neutralproduct/pr
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
GlobeNewswire58 · neutralproduct/pr
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
H.C. Wainwright reiterates Invivyd stock rating on trial data
Investing.com Analyst Ratings56 · neutralanalyst
Invivyd drops after delaying late-stage trial data for COVID therapy
Seeking Alpha34 · bearishproduct/pr
Invivyd Phase 3 data supports VYD2311 tolerability, says H.C. Wainwright
The Fly63 · neutralproduct/pr
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - Slideshow
Seeking Alpha50 · neutralgeneral
Invivyd announces results from LIBERTY Phase 3 study of VYD2311
The Fly63 · neutralproduct/pr
Invivyd, Inc. (IVVD) files 8-K
SEC 8-K50 · neutralgeneral
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
Yahoo Top58 · neutralproduct/pr
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
MarketBeat58 · neutralproduct/pr
Invivyd management to meet virtually with BTIG
The Fly55 · neutralgeneral
Invivyd to Participate in Upcoming September Investor Conferences
GlobeNewswire56 · neutralgeneral
Invivyd to Participate in Upcoming September Investor Conferences
StockTitan56 · neutralgeneral
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Cantor says Invivyd should be trading ‘meaningfully higher’ after update
The Fly67 · bullishanalyst
Invivyd names Marc Elia CEO
Seeking Alpha50 · neutralgeneral
Invivyd appoints Marc Elia CEO amid board reshuffle
TipRanks55 · neutralgeneral
Invivyd provides update on VYD2311 program, DECLARATION study
The Fly55 · neutralgeneral
Invivyd appoints Marc Elia as CEO
The Fly55 · neutralgeneral
Invivyd, Inc. (IVVD) files 8-K
SEC 8-K50 · neutralgeneral